What are NITYR® (nitisinone) Tablets?

NITYR® (nitisinone) Tablets are a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Why choose NITYR?Enroll your patients

Product

Designed for convenience, NITYR aims to give patients and their caregivers one less thing to worry about.

  • Baby aspirin-sized: 20% the volume of a single Orfadin®* (nitisinone) capsule1
  • Suitable for all age groups. It can be given as a suspension, crushed and mixed with applesauce, or swallowed whole
  • No refrigeration restrictions
  • Can be taken with or without food2
  • Bioequivalent to Orfadin®* (nitisinone) capsules3
  • Same efficacy, same safety and same side effects as Orfadin®*3
Heart in hands Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients might face. That’s why we created Cycle Vita™, our dedicated hub support program, which delivers individualized product support** at every step. Including:

  • Financial Assistance
  • Patient Nutrition Program
  • Bridge Program
Find out more
Cycle Vita Logo With Strapline
A friendly, familiar team is waiting here at Cycle Vita, for you, at every step.
Cycle Vita Logo With Strapline
A friendly, familiar team is waiting here at Cycle Vita, for you, at every step.

+1 (888) 360-8482

* Orfadin® is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc.

** Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.

References

1. Data on file: REF-00041
2. NITYR (nitisinone) Tablets. Prescribing Information. Cycle Pharmaceuticals Ltd
3. Data on file: REF-00047